The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial

@article{Ballard2009TheDA,
  title={The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial},
  author={Clive G Ballard and Maria Luisa Hanney and Megan Theodoulou and Simon Douglas and Rupert McShane and Katja Kossakowski and Randeep Gill and Edmund Juszczak and Ly-Mee Yu and Robin J. Jacoby},
  journal={The Lancet Neurology},
  year={2009},
  volume={8},
  pages={151-157}
}
View on Elsevier
doi.org
524 Citations
Highly Influential Citations
16
Background Citations
140
Methods Citations
8
Results Citations
13

524 Citations

Citation Type

Citation Type

A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Continued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer disease
  • C. Hirsch
  • Psychology, Medicine
    Annals of Internal Medicine
  • 2009
TLDR
In patients with Alzheimer disease, continued use of antipsychotic drugs increased long-term mortality, and the results show a sustained higher mortality rate among patients continuing on APDs.
Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
TLDR
A lack of effectiveness and a high incidence of side effects with 4 commonly prescribed atypical antipsychotics across diagnostic groups in patients over age 40 are found, with relatively few differences among the drugs.
Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials
  • S. Gentile
  • Psychology, Medicine
    Psychopharmacology
  • 2010
TLDR
Because of their undemonstrated effectiveness, SGAs should be avoided in patients with dementia complicated by psychotic and/or behavioural symptoms and further researches are urgently needed to identify useful pharmacological strategies that can be used to improve the clinical condition of such patients and to reduce burden to caregivers when behavioural interventions are ineffective.
How Legislation on Decisional Capacity Can Negatively Affect the Feasibility of Clinical Trials in Patients with Dementia
TLDR
The AdCare study, a non-profit, randomized, placebo-controlled, double-blind, multicentre, pragmatic trial coordinated by the Italian National Institute of Health, aimed to evaluate the long-term safety and efficacy profiles of three atypical antipsychotic drugs in treating psychosis, aggression and agitation in outpatients with AD.
How legislation on decisional capacity can negatively affect the feasibility of clinical trials in patients with dementia.
TLDR
The AdCare study showed that an excessively rigid regulation can become a major obstacle while carrying out therapeutic research with incapacitated persons.
Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia.
TLDR
There is low-quality evidence that antipsychotics may be successfully discontinued in older people with dementia and NPS who have been taking antipsychotic drugs for at least three months, and that discontinuation may have little or no important effect on behavioural and psychological symptoms.
Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review
TLDR
There is limited evidence to support the use of some atypical antipsychotics and other medications for NPS in LTC populations, however, the generally modest efficacy and risks of adverse events highlight the need for the development of safe and effective pharmacological and non-pharmacological interventions for this population.
Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review
TLDR
Choice of observational study design is critical in studying the adverse effects of antispychotics and good quality observational studies are required, that employ appropriate study designs that are robust towards unmeasured confounding, to confirm the potential excess risk of hip fracture and pneumonia with antipsychotics.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)
TLDR
For most patients with AD, withdrawal of neuroleptics had no overall detrimental effect on functional and cognitive status, and there was some evidence to suggest that those patients with initial NPI ≥ 15 benefited on neuropsychiatric symptoms from continuing treatment.
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
TLDR
Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo, and this risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
  • L. Schneider, K. Dagerman, P. Insel
  • Psychology, Medicine
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2006
TLDR
Small statistical effect sizes on symptom rating scales support the evidence for the efficacy of aripiprazole and risperidone.
A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.
TLDR
A standardized evaluation with an instrument such as the NPI may be a clinical indicator of which people with dementia are likely to benefit from discontinuation of neuroleptic treatment.
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
TLDR
Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease.
Atypical antipsychotics for aggression and psychosis in Alzheimer's disease
TLDR
Evidence suggests that risperidone and olanzapine are useful in reducing aggression and ris peridone reduces psychosis, but both are associated with serious adverse cerebrovascular events and extrapyramidal symptoms.
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
TLDR
Neither quetiapine nor rivastigmine are effective in the treatment of agitation in people with dementia in institutional care and compared with placebo, quetoapine is associated with significantly greater cognitive decline.
A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
  • B. Pollock, B. Mulsant, K. Huber
  • Psychology, Medicine
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2007
TLDR
Findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.
Donepezil for the treatment of agitation in Alzheimer's disease.
TLDR
In this 12-week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer's disease.
Risk of death in elderly users of conventional vs. atypical antipsychotic medications.
TLDR
Conventional antipsychotic medications are at least as likely as atypical agents to increase the risk of death among elderly persons and that conventional drugs should not be used to replace atypicals agents discontinued in response to the FDA warning.
...
1
2
3
...